AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event

Rhea-AI Summary

AIM ImmunoTech (NYSE American: AIM) will host a live virtual investor Closing Bell Event on Thursday, April 16, 2026 at 4:00 PM ET. CEO Thomas K. Equels will give a corporate overview and business outlook and take live questions from investors.

A live video webcast will be available on the company Events page and a replay will be posted two hours after the presentation and accessible for 90 days.

News Market Reaction – AIM

-6.24%

5 alerts

-6.24% Session close to close

+5.0% Peak Tracked

-2.7% Trough Tracked

$4.45M Market Cap

0.0x Rel. Volume

In the Apr 9 session, AIM declined 6.24%, reflecting a notable negative market reaction. Argus tracked a peak move of +5.0% during that session. Argus tracked a trough of -2.7% from its starting point during tracking. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved -6.2% in the session following this news. A negative reaction despite this being a r...

Analysis

The stock moved -6.2% in the session following this news. A negative reaction despite this being a routine investor-relations event would fit AIM’s pattern of volatility around news, including past declines after positive clinical updates. The company’s use of its $100 million shelf registration and recent rights offerings underscores ongoing financing and dilution considerations that could weigh on sentiment, even when announcements are focused on corporate presentations rather than new fundamentals.

Key Figures

Event date: April 16, 2026 Event time: 4:00 PM ET Replay availability delay: 2 hours +1 more

4 metrics

Event date April 16, 2026 Scheduled date of Virtual Investor Closing Bell Event

Event time 4:00 PM ET Start time of live webcast with CEO

Replay availability delay 2 hours Replay becomes available two hours after live presentation

Replay window 90 days Webcast replay accessible for 90 days on company website

Historical Context

5 past events · Latest: Mar 18 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 18	Patent approval Japan	Positive	+43.7%	Final approval of Japanese cancer therapy patent covering Ampligen combinations.
Mar 06	Rights offering closing	Neutral	+4.3%	Closing of rights offering generating about $1.8M total subscriptions.
Mar 04	Rights offering results	Neutral	-1.3%	Preliminary rights offering results for estimated $1.8M gross proceeds.
Mar 02	Phase 3 trial planning	Positive	-14.9%	Agreement to design Phase 3 Ampligen trial after positive Phase 2 DURIPANC signals.
Feb 27	Rights offering update	Neutral	-8.3%	Updated terms and reminder of March 3 expiration for rights offering.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news has produced mixed reactions: some positive clinical and IP updates saw strong gains, while other positive or neutral items, especially around financings, coincided with selloffs.

Recent Company History

Over the past few months, AIM has combined clinical, IP, and financing developments. On Mar 18, 2026, a Japanese patent approval tied to Ampligen and checkpoint inhibitors saw a strong 43.66% gain. Multiple rights-offering milestones between Feb 27 and Mar 6, 2026 raised about $1.8M with mixed price reactions. A Mar 2, 2026 agreement to plan a Phase 3 Ampligen trial in late-stage pancreatic cancer, despite positive Phase 2 signals, was followed by a -14.89% move. Today’s investor event notice fits into this ongoing communication cadence.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Thursday, April 16^th at 4:00 PM ET 

Register for the event here

OCALA, Fla., April 09, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM, will participate in a Virtual Investor Closing Bell Event on Thursday, April 16, 2026, at 4:00 PM ET. 

Mr. Equels will provide a corporate overview and business outlook. In addition to the moderated discussion, investors and interested parties will have the opportunity to submit questions live during the event. The Company will answer as many questions as possible in the time allowed.  

A live video webcast of the presentation will be available on the Events page of the Company’s website (aimimmuno.com). A webcast replay will become available two hours following the live presentation and will be accessible for 90 days.  

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer, a lethal and unmet global health problem. Ampligen is a dsRNA and highly selective TLR3 agonist immuno-modulator that has shown broad-spectrum activity in clinical trials.

For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.

Investor Contact:

JTC Team, LLC
Jenene Thomas
908.824.0775
AIM@jtcir.com

FAQ

When is the AIM (AIM) Virtual Investor Closing Bell Event with CEO Thomas K. Equels?

The event is scheduled for Thursday, April 16, 2026 at 4:00 PM ET. According to AIM, the CEO will provide a corporate overview and business outlook and take live investor questions during the webcast.

How can investors watch the AIM (AIM) webcast on April 16, 2026?

Investors can watch via the live video webcast on the company Events page at aimimmuno.com. According to AIM, the presentation will stream live and accept submitted questions during the session.

Will AIM (AIM) provide a replay of the April 16, 2026 Closing Bell Event, and for how long?

Yes. A replay will be available two hours after the live presentation and remain accessible for 90 days. According to AIM, the replay will be posted on the company Events page for on-demand viewing.

Who will present at AIM ImmunoTech's April 16, 2026 investor event and what will they cover?

Thomas K. Equels, CEO of AIM, will present and deliver a corporate overview and business outlook. According to AIM, the session includes a moderated discussion and live Q&A with investors.

Can investors ask questions during the AIM (AIM) April 16, 2026 webcast and how are they handled?

Yes. Investors may submit questions live during the event and the company will answer as many as time allows. According to AIM, the moderated format prioritizes live interaction with attendees.

Where will information and registration details for the AIM (AIM) Closing Bell Event be posted?

Registration details and the live webcast link will be posted on the company Events page at aimimmuno.com. According to AIM, interested parties should register on the site to access the webcast.